GlassScriptPhysician profile
Joseph Brannigan
NPI 1417921214
$1,746.61
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $166 · 2021: $370 · 2022: $405 · 2023: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $237.67 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $175.39 | 2019 | |
| Nxstage Medical, INC. | $171.29 | 2023 | Nxstage System One |
| Amgen INC. | $167.42 | 2019-2022 | |
| Abbott Laboratories | $133.23 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $132.06 | 2019-2023 | Jynarque |
| Vifor Pharma, INC. | $101.72 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $100.31 | 2019-2022 | |
| Akebia Therapeutics INC | $69.51 | 2021 | |
| Mallinckrodt Hospital Products INC. | $68.28 | 2021-2022 | |
| Horizon Therapeutics Plc | $65.39 | 2020-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $48.70 | 2022 | |
| Opko Pharmaceuticals, LLC | $46.41 | 2021 | |
| Alexion Pharmaceuticals, INC. | $39.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.44 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $30.32 | 2021-2023 | Benlysta |
| Vbi Vaccine (Delaware) INC. | $17.86 | 2022 | |
| Aurinia Pharma U.S., INC. | $17.72 | 2022 | |
| Daiichi Sankyo INC. | $17.36 | 2021 | |
| Recordati_rare_diseases_inc. | $15.75 | 2021 | |
| Shire North American Group INC | $15.69 | 2019 | |
| Genzyme Corporation | $15.54 | 2020 | |
| Travere Therapeutics, INC. | $14.75 | 2022 | |
| Biomerieux INC | $9.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Brannigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.